The previously communicated study at the clinic of Oncology, at Skåne University Hospital, has now been granted an ethical approval. The purpose of the study is to investigate the extent to which VibroSense Meter can be used to detect nerve damage (neuropathy) that occurs in the treatment of colorectal cancer with Oxaliplatin. 30 patients will be included in the study and data collection is expected to be completed in November 2018. In an extension, the goal is to develop personalized treatment, aided by the company's product VibroSense Meter, to reduce or prevent nerve damage caused by chemotherapy.
Press Releases and News
Subscribe
Subscribe by clicking the letter icon in the "Subscribe" box at the top right of our news page on Cision. You will then receive an email asking you to confirm your email address, after which you can mark which mailings you want to subscribe to.